CN1255064A - α－甲基－对－酪氨酸抑制虹膜黑素细胞中黑色素的产生的用途 - Google Patents

α－甲基－对－酪氨酸抑制虹膜黑素细胞中黑色素的产生的用途 Download PDF

Info

Publication number
CN1255064A
CN1255064A CN98804999A CN98804999A CN1255064A CN 1255064 A CN1255064 A CN 1255064A CN 98804999 A CN98804999 A CN 98804999A CN 98804999 A CN98804999 A CN 98804999A CN 1255064 A CN1255064 A CN 1255064A
Authority
CN
China
Prior art keywords
tyrosine
methyl
alpha
iris
latanoprost
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98804999A
Other languages
English (en)
Chinese (zh)
Inventor
F·德拉戈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Publication of CN1255064A publication Critical patent/CN1255064A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN98804999A 1997-04-22 1998-04-21 α－甲基－对－酪氨酸抑制虹膜黑素细胞中黑色素的产生的用途 Pending CN1255064A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI97A000939 1997-04-22
IT97MI000939A IT1291633B1 (it) 1997-04-22 1997-04-22 Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride

Publications (1)

Publication Number Publication Date
CN1255064A true CN1255064A (zh) 2000-05-31

Family

ID=11376994

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98804999A Pending CN1255064A (zh) 1997-04-22 1998-04-21 α－甲基－对－酪氨酸抑制虹膜黑素细胞中黑色素的产生的用途

Country Status (22)

Country Link
US (1) US6359001B1 (enExample)
EP (1) EP0977575B1 (enExample)
JP (1) JP2001521540A (enExample)
KR (1) KR20010020202A (enExample)
CN (1) CN1255064A (enExample)
AT (1) ATE227577T1 (enExample)
AU (1) AU732046B2 (enExample)
CA (1) CA2287887A1 (enExample)
DE (1) DE69809408T2 (enExample)
DK (1) DK0977575T3 (enExample)
ES (1) ES2187028T3 (enExample)
HU (1) HUP0002100A3 (enExample)
IL (1) IL132503A (enExample)
IT (1) IT1291633B1 (enExample)
NO (1) NO995122L (enExample)
NZ (1) NZ500435A (enExample)
PL (1) PL189304B1 (enExample)
PT (1) PT977575E (enExample)
RU (1) RU2218159C2 (enExample)
SI (1) SI0977575T1 (enExample)
SK (1) SK284255B6 (enExample)
WO (1) WO1998047515A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104220057A (zh) * 2012-01-17 2014-12-17 迪美公司 药物组合物和方法
US9549969B2 (en) 2012-01-17 2017-01-24 Tyme, Inc. Pharmaceutical compositions and methods
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
CN116035151A (zh) * 2023-01-18 2023-05-02 云南贝泰妮生物科技集团股份有限公司 一种刺梨闪释粉及其制备方法和应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20013174A3 (cs) 1999-03-05 2002-02-13 The Procter & Gamble Company C16 nenasycené FP-selektivní prostaglandinové analogy
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
WO2010087983A1 (en) * 2009-01-29 2010-08-05 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
US9744237B2 (en) * 2009-01-29 2017-08-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
US20120076848A1 (en) * 2009-07-22 2012-03-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US9763903B2 (en) 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
ES2738248B2 (es) * 2018-06-21 2023-03-10 Consejo Superior Investigacion Uso de inhibidores de la tirosina hidroxilasa para el tratamiento del aneurisma de aorta
WO2020018291A1 (en) 2018-07-19 2020-01-23 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
WO2020232227A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04117313A (ja) * 1990-09-06 1992-04-17 Kanebo Ltd 美白化粧料

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104220057A (zh) * 2012-01-17 2014-12-17 迪美公司 药物组合物和方法
US9549969B2 (en) 2012-01-17 2017-01-24 Tyme, Inc. Pharmaceutical compositions and methods
CN104220057B (zh) * 2012-01-17 2017-11-03 迪美公司 药物组合物和方法
US9895425B2 (en) 2012-01-17 2018-02-20 Tyme, Inc. Pharmaceutical compositions and methods
CN107714684A (zh) * 2012-01-17 2018-02-23 迪美公司 包含α‑甲基‑DL‑酪氨酸的药物组合物及其应用
US10010590B2 (en) 2012-01-17 2018-07-03 Tyme, Inc. Pharmaceutical compositions and methods
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
US10307465B2 (en) 2012-01-17 2019-06-04 Tyme, Inc. Pharmaceutical compositions and methods
US10507198B2 (en) 2012-01-17 2019-12-17 Tyme, Inc. Pharmaceutical compositions and methods
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
US11052068B2 (en) 2012-01-17 2021-07-06 Tyme, Inc. Pharmaceutical compositions and methods
US11103559B2 (en) 2012-01-17 2021-08-31 Tyme, Inc. Pharmaceutical compositions and methods
CN116035151A (zh) * 2023-01-18 2023-05-02 云南贝泰妮生物科技集团股份有限公司 一种刺梨闪释粉及其制备方法和应用

Also Published As

Publication number Publication date
JP2001521540A (ja) 2001-11-06
IL132503A0 (en) 2001-03-19
IL132503A (en) 2004-06-20
SI0977575T1 (en) 2003-04-30
NO995122D0 (no) 1999-10-21
DK0977575T3 (da) 2003-03-10
US6359001B1 (en) 2002-03-19
SK284255B6 (sk) 2004-12-01
DE69809408D1 (de) 2002-12-19
KR20010020202A (ko) 2001-03-15
IT1291633B1 (it) 1999-01-11
PL336386A1 (en) 2000-06-19
SK142499A3 (en) 2000-09-12
EP0977575B1 (en) 2002-11-13
WO1998047515A1 (en) 1998-10-29
AU732046B2 (en) 2001-04-12
PT977575E (pt) 2003-03-31
HUP0002100A2 (hu) 2000-11-28
HUP0002100A3 (en) 2003-05-28
AU7646298A (en) 1998-11-13
DE69809408T2 (de) 2003-07-10
NO995122L (no) 1999-12-21
ES2187028T3 (es) 2003-05-16
CA2287887A1 (en) 1998-10-29
RU2218159C2 (ru) 2003-12-10
ITMI970939A1 (it) 1998-10-22
ATE227577T1 (de) 2002-11-15
NZ500435A (en) 2001-09-28
ITMI970939A0 (enExample) 1997-04-22
EP0977575A1 (en) 2000-02-09
PL189304B1 (pl) 2005-07-29

Similar Documents

Publication Publication Date Title
CN1255064A (zh) α－甲基－对－酪氨酸抑制虹膜黑素细胞中黑色素的产生的用途
Yamasaki et al. Prostaglandin as a mediator of bone resorption induced by experimental tooth movement in rats
EP2238982B1 (en) Therapeutic agent for soft tissue sarcoma
EP0682521B1 (en) treatment of periodontal disease with misoprostol
Wick Levodopa and Dopamine Analogs: Melanin Precursors as Antitumor Agents in Experimental Human and Murine Leukemia 1, 2, 3
CA2402160A1 (en) Heparinase iii and uses thereof
CA2073084C (en) The use of sulphur-containing carboxylic acids to combat physiologically-induced excitatory disorders and diseases related thereto as well as allergic diseases and also the preparation of corresponding medicaments
Moy et al. Phenytoin modulates connective tissue metabolism and cell proliferation in human skin fibroblast cultures
FR2511867A1 (fr) Formulations pharmaceutiques comprenant de l'insuline et de la pro-insuline humaines
Abemayor The effects of retinoic acid on the in vitro and in vivo growth of neuroblastoma cells
CN116725995B (zh) γ-氨基丁酸在预防和/或改善由香烟烟雾引起的牙龈损伤的用途及实现该用途的方法
HK1027978A (en) THE USE OF α-METHYL-P-TYROSINE TO INHIBIT MELANDIN PRODUCTION IN IRIS MELANOCYTES
CN113995742A (zh) 包含丙戊酸的美白组合物及其用途
CA2570926C (fr) Utilisation cosmetique d'au moins un tetrapeptide naturel ac-n-ser-asp-lys-pro ou un de ses anologues en tant qu'agent antivieillissement et restructurant de la peau
Weiss et al. Effect of ethanol on ethylene glycol oxidation by mammalian liver enzymes
AU645071B2 (en) Use of dermatan sulphate for the prevention and therapy of cerebral aging and of central nervous system functional deficit states DO NOT SEAL - CASE TO LAPSE
Vázquez et al. Congenital glaucoma and cutis marmorata telangiectatica: report of the second case
JPH06219933A (ja) メラニンの分解方法とメラニンの分解性物質
WO1998052577A1 (en) Ganglioside gm3 induced apoptosis of neural cells
CZ372099A3 (cs) Použití alfa-methyl-p-tyrosinu k inhibici produkce melaninu v pigmentových buňkách duhovky
CN110292627A (zh) 用于抑制口腔鳞状细胞癌迁移和侵袭的多肽药物及其用途
Jackson Treatment of superficial epitheliomatosis with an ointment containing demecolcin
CN120437105A (zh) 咖啡酰丁二胺在制备乙酰胆碱酯酶抑制剂中的应用
CN116082486A (zh) 一种具有抑制黑色素生成活性的多肽及其应用
CN119235839A (zh) 双醋瑞因及其衍生物在制备抑制纤维化和促进局部组织再生的药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1027978

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication